Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724282 · ClinicalTrials.gov registry record · Phase 4
Treatment of Insomnia and Glucose Metabolism
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00724282 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 20 participants.
The verdict
NCT00724282, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug Administration for the treatment of people who complain of trouble falling or staying asleep. This study will examine the hypothesis that the use of Eszopiclone (Lunesta) to improve the sleep of people with insomnia may also improve the use of sugar in their body.
Interventions
- DRUG Placebo
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724282
The ClinicalTrials.gov registry entry for NCT00724282 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00724282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724282 about?
NCT00724282 is a clinical study titled "Treatment of Insomnia and Glucose Metabolism". Available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug Administration for the treatment o...
What is the current status of trial NCT00724282?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2008-04. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00724282?
The interventions under investigation include: Placebo (DRUG), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00724282?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.